title: [Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
abstract: In relapsing-remitting multiple sclerosis, only parenteral immunomodulatory treatments existed for 15 years, until 2010. In recent years, novel disease-modifying agents became available with new mechanisms of action and oral application, which expanded therapeutic options. Thus, when making therapeutic decisions, more and new aspects should be considered, and the daily practice of patient management has been changed due to the different profile of possible side-effects. The authors review the mechanism of action, pharmacokinetics, studies regarding efficacy, side-effects of first- and second line oral disease-modifying treatments and provide practical guide of their everyday usage.
authors.affiliation: Semmelweis University Department of Neurology, Budapest, Hungary. iljicsov.anna@med.semmelweis-univ.hu.
authors.forename: Anna
authors.initials: A
authors.lastname: Iljicsov
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Pál
authors.forename: Magdolna
authors.initials: M
authors.lastname: Simó
mesh_terms: D000284:Administration, Oral; D003437:Crotonates / Q000008:administration & dosage* / Q000494:pharmacology; D000069462:Dimethyl Fumarate / Q000008:administration & dosage* / Q000494:pharmacology; D000068876:Fingolimod Hydrochloride / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000494:pharmacology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology; D009570:Nitriles; D014052:Toluidines / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D003437:Crotonates; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents; D009570:Nitriles; D014052:Toluidines; C527525:teriflunomide; D000069462:Dimethyl Fumarate; D000068876:Fingolimod Hydrochloride